Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790816 · ClinicalTrials.gov registry record · Phase 1
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 500
- Enrollment target
NCT00790816 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 500 participants.
The verdict
NCT00790816, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 500 participants
- Enrollment target
Study Summary
This study is designed to provide continued access to lapatinib as monotherapy or as part of a combination regimen to cancer subjects who are currently participating in a phase I trial that has met its study objectives.
Interventions
- DRUG Lapatinib
- DRUG Lapatinib in combination with an anti-cancer agent
- DRUG Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2008-10 |
| Est. Completion | 2016-08-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00790816
The ClinicalTrials.gov registry entry for NCT00790816 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lapatinib is the first listed.
NCT00790816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00790816 about?
NCT00790816 is a clinical study titled "Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents". This study is designed to provide continued access to lapatinib as monotherapy or as part of a combination regimen to cancer subjects who are currently participating in a phase I trial that has met its study objectives.
What is the current status of trial NCT00790816?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 500 participants. The study started on 2008-10. Estimated completion is 2016-08-19.
What interventions are being tested in trial NCT00790816?
The interventions under investigation include: Lapatinib (DRUG), Lapatinib in combination with an anti-cancer agent (DRUG), Lapatinib in combination with an anti-cancer agent as specified by parent protocol (DRUG).
Who is sponsoring clinical trial NCT00790816?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.